Therefore, it can be suggested that the disappointing results of the anti-TNF-α clinical trials against MS were due to the inhibition of previously unrecognized beneficial effects of this cytokine and/or unspecific receptor activation. This evidence concerns the gene TNF and myeloid sarcoma.